Education
About Us
Working with TipRanks
Follow Us
Tango Therapeutics (TNGX)
NASDAQ:TNGX
Total Valuation
Tango Therapeutics has a market cap or net worth of $519.21M. The enterprise value is $617.86M.
Market Cap$519.21M
Enterprise Value$617.86M
Share Statistics
Tango Therapeutics has 108,394,190 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding108,394,190
Owned by Insiders50.66%
Owned by Institutions0.25%
Financial Efficiency
Tango Therapeutics’s return on equity (ROE) is -0.65 and return on invested capital (ROIC) is -51.94%.
Return on Equity (ROE)-0.65
Return on Assets (ROA)-0.41
Return on Invested Capital (ROIC)-51.94%
Return on Capital Employed (ROCE)-0.52
Revenue Per Employee271.41K
Profits Per Employee-840.66K
Employee Count155
Asset Turnover0.13
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Tango Therapeutics is -2.59. Tango Therapeutics’s PEG ratio is -0.19.
PE Ratio-2.59
PS Ratio0.00
PB Ratio2.55
Price to Fair Value1.69
Price to FCF-5.45
Price to Operating Cash Flow-5.84
PEG Ratio-0.19
Income Statement
In the last 12 months, Tango Therapeutics had revenue of 42.07M and earned -130.30M in profits. Earnings per share was -1.19.
Revenue42.07M
Gross Profit42.07M
Operating Income-145.59M
Pretax Income-130.09M
Net Income-130.30M
EBITDA-143.10M
Earnings Per Share (EPS)-1.19
Cash Flow
In the last 12 months, operating cash flow was -135.34M and capital expenditures -610.00K, giving a free cash flow of -135.95M billion.
Operating Cash Flow-135.34M
Free Cash Flow-135.95M
Free Cash Flow per Share-1.25
Dividends & Yields
Tango Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.88
52-Week Price Change-49.69%
50-Day Moving Average2.15
200-Day Moving Average3.81
Relative Strength Index (RSI)77.36
Average Volume (3m)3.92M
Important Dates
Tango Therapeutics upcoming earnings date is Aug 6, 2025, TBA Not Confirmed.
Last Earnings DateMay 12, 2025
Next Earnings DateAug 6, 2025
Ex-Dividend Date―
Financial Position
Tango Therapeutics as a current ratio of 6.98, with Debt / Equity ratio of 16.49%
Current Ratio6.98
Quick Ratio6.98
Debt to Market Cap0.11
Net Debt to EBITDA0.23
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Tango Therapeutics has paid 208.00K in taxes.
Income Tax208.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Tango Therapeutics EV to EBITDA ratio is -2.09, with an EV/FCF ratio of -2.30.
EV to Sales7.24
EV to EBITDA-2.09
EV to Free Cash Flow-2.30
EV to Operating Cash Flow-2.32
Balance Sheet
Tango Therapeutics has $216.72M in cash and marketable securities with $36.95M in debt, giving a net cash position of -$179.78M billion.
Cash & Marketable Securities$216.72M
Total Debt$36.95M
Net Cash-$179.78M
Net Cash Per Share-$1.66
Tangible Book Value Per Share$1.83
Margins
Gross margin is 83.80%, with operating margin of -346.09%, and net profit margin of -309.73%.
Gross Margin83.80%
Operating Margin-346.09%
Pretax Margin-309.24%
Net Profit Margin-309.73%
EBITDA Margin-346.09%
EBIT Margin-346.09%
Analyst Forecast
The average price target for Tango Therapeutics is $12.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$12.00
Price Target Upside150.52% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast10.10%
EPS Growth Forecast-7.25%